Enterome Completes 46.3 Million ($52.6 Million) Financing to Progress the Clinical Development of Its Therapeutic Pipeline – BioSpace
Posted: June 25, 2020 at 8:44 pm
Lead 'OncoMimics' candidate EO2401 planned to start first clinical trials for Glioblastoma and Adrenal Tumors during mid-2020
PARIS and CAMBRIDGE, Massachusetts, June 25, 2020 /PRNewswire/ -- ENTEROME SA, a clinical-stage biopharmaceutical company leveraging its unique knowledge of the microbiome-immunoinflammation axis to develop next-generation therapeutics, today announces a new financing totaling 46.3 million ($52.6million) to progress the clinical development of its therapeutic pipeline, including the first clinical trials of EO2401, a novel 'OncoMimic' cancer immunotherapy.
As part of this financing, Enterome has closed a Series E round with new investors including SymBiosis, LLC, a microbiome-focused investment vehicle, and Takeda Pharmaceutical Company Limited. Existing Enterome investors Seventure, Health for Life Capital, Principia, Omnes Capital and Nestl Health Science also participated in the round. In addition, Enterome has made a first drawdown from a loan facility provided by the European Investment Bank (EIB) under a 2018 agreement.
Enterome will use the funds primarily to progress EO2401, an innovative, off-the-shelf immuno-oncology candidate, into the clinic in two cancer indications. The two Phase 1/2 clinical studies in glioblastoma and adrenal tumors, respectively, are planned to start during mid-2020. EO2401 is the first clinical candidate derived from Enterome's first-in-class OncoMimics platform.
OncoMimics are microbiome-derived peptide antigens that closely mimic antigens expressed by tumor cells; they are selected based on their ability to trigger the rapid activation of memory T-cells that respond to gut bacteria and to direct a targeted cell-killing immune response against the tumor. EO2401 combines three OncoMimics present in aggressive cancers such as glioblastoma and adrenal malignancies.
Enterome expects its second OncoMimic candidate, EO2463, a new multi-peptide cancer immunotherapy, to enter the clinic in 2021 for the treatment of B-cell malignancies (lymphomas and leukaemias).
Enterome is also pursuing the development of its proprietary, next-generation EndoMimics platform, which is designed to produce a new generation of biologics with high potency and unique tolerability. These novel peptide/protein therapeutics are being developed for unmet medical needs in metabolic and inflammatory diseases.
Enterome's lead EndoMimic candidate, EM101, is a human hormone mimetic produced by commensal bacteria. It is currently in pre-clinical development as a potential novel therapy for inflammatory bowel disease (IBD).
Enterome will continue to invest in developing its world-leading Metasecretome technology, of which both the OncoMimics and EndoMimics platforms are key components.
Pierre Belichard, Chief Executive Officer of Enterome, said: "We are extremely pleased to have completed this significant financing round, which represents an attractive balance of dilutive and non-dilutive funds. The financing will be used to progress EO2401, the first targeted immunotherapy generated from our unique OncoMimics platform. This platform capitalizes on the well-described, constant interaction between the microbiome and the immune system, resulting in a pool of memory T cells directed against specific commensal bacterial antigens that we have identified. We have discovered that some of these antigens bear striking similarity to those present on multiple cancer types and can induce a targeted, anti-tumor response hence 'OncoMimics'. We are exploiting this internal discovery to develop highly effective, off-the-shelf immunotherapies against cancers with significant unmet medical need. We look forward to starting the clinical development of this exciting new immunotherapy soon."
Enterome will also use the proceeds to support its global partner Takeda Pharma to deliver proof-of-concept clinical data with EB8018 (sibofimloc/TAK-018), an oral FimH blocker for the treatment of Crohn's disease.
"Takeda's participation in this fundraising round builds on our long-standing productive collaboration with Enterome which is focused on the clinical development of sibofimloc, an oral FimH blocker for the treatment of Crohn's disease," said Asit Parikh, M.D., Ph. D., Head, Gastroenterology Therapeutic Area Unit at Takeda.
About Enterome
Enterome is a world leader in the discovery and development of novel pharmaceuticals based on its unrivalled understanding of the interaction between the gut microbiome and the immune system (the 'microbiome-immunoinflammation axis'). Enterome is leveraging this expertise to develop a pipeline of clinical and pre-clinical candidates (small molecules, proteins and peptides) with a focus on cancer, autoimmune, inflammatory and metabolic diseases.
Enterome has two unique platforms that are generating highly promising drug candidates:
These highly productive platforms have been created using Enterome's world-leading Metasecretome technology, which gives it an unrivalled ability to generate precision drugs by using the natural reservoir of thousands of safe and tolerized effector proteins that are produced by the gut bacteria.
Enterome's most advanced drug candidate is EB8018 (also referred to as sibofimloc/TAK-018), which selectively blocks the virulence factor FimH, is advancing through clinical trials in Crohn's disease. EB8018 has been partnered with Takeda globally, with Enterome retaining a significant profit share in the US.
Enterome is headquartered in Paris (France) with operations in Boston (US) and is backed by leading venture capital investors.
Contacts EnteromePierre Belichard, CEOTel. +33 1 75 77 27 87media@enterome.com
Media Relations Mark Swallow / Sylvie Berrebi / David DibleCitigate Dewe RogersonTel. +44 207 638 9571enterome@citigatedewerogerson.com
Investor RelationsMelody CareyRx Communications GroupTel. +1 917 322 2571mcarey@rxir.com
View original content:http://www.prnewswire.com/news-releases/enterome-completes-46-3-million-52-6-million-financing-to-progress-the-clinical-development-of-its-therapeutic-pipeline-301083315.html
SOURCE Enterome
Continue reading here:
Enterome Completes 46.3 Million ($52.6 Million) Financing to Progress the Clinical Development of Its Therapeutic Pipeline - BioSpace
- Denial of hormones is more than women should bear - The Medical Republic - February 23rd, 2024
- Katy couple discovers benefits of hormone replacement therapy - FOX 26 Houston - February 13th, 2024
- Gender-affirming care clinic in Thunder Bay, Ont., closes, leaving patients with limited options - CBC.ca - February 5th, 2024
- What It Means That Lisa Rinna Is On HRT For Menopause - Women's Health - January 11th, 2024
- Lisa Rinna Was Initially 'Very Scared' of Hormone Replacement Therapy. She Isn't the Only One - The Messenger - January 11th, 2024
- MrBeast's Kris Tyson Shares Before and After Photos Following 1 Year of Hormone Replacement Therapy - PEOPLE - January 11th, 2024
- Lisa Rinna Was 'Really Scared' to Undergo Hormone Replacement Therapy for Menopause Symptoms: 'I Haven't ... - Yahoo Entertainment - January 11th, 2024
- Kris Tyson Before And After HRT Pictures - BuzzFeed - January 11th, 2024
- Hormone replacement therapy and early menopause tied heightened risk of rheumatoid arthritis - Medical Dialogues - January 11th, 2024
- Open for Business: Alpine Wellness opens new clinic for integrative medicine and hormone health - KOLO - January 3rd, 2024
- Is Hormone Replacement Therapy Right for You? What to Know - Motherly Inc. - January 3rd, 2024
- Easy as visiting the GP: Doctors push for accessible hormone treatment as childrens waitlist swells - The Age - January 3rd, 2024
- How to Balance Hormones: 11 Nondrug and Drug Options - Verywell Health - December 25th, 2023
- Hormone Replacement Therapy Market Poised for a Remarkable US$ 23,729.6 Million Valuation by 2034, Fueled by a ... - Yahoo Finance - December 25th, 2023
- Home - CHS Hormone - December 6th, 2023
- My teenage son was indoctrinated by the trans cult from the classroom to the clinic: Mother left 'grieving' fo - Daily Mail - November 27th, 2023
- Hormone Evaluation and Replacement Therapy | Amen Clinics - November 2nd, 2023
- Depression can hit hard during the winter months, here's how to prevent it - NewsCenterMaine.com WCSH-WLBZ - October 16th, 2023
- As a study finds a stable weight is key to living longer, a leading nutritionist's guide on how to... Escape t - Daily Mail - October 16th, 2023
- I worked at the Tavistock gender clinic. Closing it was the right move - The Dallas Morning News - April 26th, 2023
- What causes hormonal imbalance and how to avoid it? - GMA News Online - March 23rd, 2023
- Thyroid Hormone: What It Is & Function - Cleveland Clinic - December 20th, 2022
- Menopause - Symptoms and causes - Mayo Clinic - December 20th, 2022
- Human Chorionic Gonadotropin: Hormone, Purpose & Levels - Cleveland Clinic - December 20th, 2022
- Polycystic ovary syndrome (PCOS) - Symptoms and causes - Mayo Clinic - December 20th, 2022
- Hypothyroidism: Symptoms, Causes, Treatment & Medication - Cleveland Clinic - December 20th, 2022
- Postpartum depression - Symptoms and causes - Mayo Clinic - December 20th, 2022
- Let's Talk Sex | Unpacking the Mystery of PCOS: Causes, Symptoms and Treatments - News18 - December 20th, 2022
- Masculinizing hormone therapy - Mayo Clinic - October 16th, 2022
- Human Growth Hormone (hGH) - Cleveland Clinic - October 16th, 2022
- Chronic stress puts your health at risk - Mayo Clinic - October 16th, 2022
- Menstrual Migraines (Hormone Headaches) - Cleveland Clinic - October 16th, 2022
- Acromegaly: What It Is, Causes, Symptoms & Treatment - Cleveland Clinic - October 16th, 2022
- Hormone Therapy and Shoulder Pain During Menopause - Healthline - October 16th, 2022
- CHOICES Reproductive Health clinic now open in Carbondale - WSIL TV - October 16th, 2022
- Helping Reduce Your Risk of Breast Cancer ThedaCare - ThedaCare - October 16th, 2022
- HIV patients abused and humiliated - News24 - October 16th, 2022
- Recommended Approaches to Treatment for Early-Stage HER2+ Breast Cancer - Targeted Oncology - October 16th, 2022
- Diabetes and the gut: How a bacterial protein may impact insulin - Medical News Today - October 16th, 2022
- TUCKER CARLSON: The Democratic Party is replacing parents with itself - Fox News - October 16th, 2022
- 'You will get your heart broken. Not might, will.': Foster mom shares heartwarming adoption after infertility, heartbreak - Love What Matters - October 16th, 2022
- Everything You Need To Know About Hormone Replacement Therapy - Health Digest - August 11th, 2022
- What is hormone therapy for breast cancer? - MD Anderson - August 11th, 2022
- Brevard LGBTQ clinic responds to proposed restrictions on trans healthcare - Florida Today - August 11th, 2022
- Aldosterone, a hormone that prevents dehydration, is linked to worsening kidney disease, study suggests - STAT - August 11th, 2022
- 8 reasons why you wake up tired, and how to fix it - WDJT - August 11th, 2022
- What We Learned About Steve Jobs' Health After His Death - Health Digest - August 11th, 2022
- Hormonal Acne: Causes, Treatment, And How To Prevent It - Women's Health - August 11th, 2022
- Bastion Health Announces the addition of Dr. Justin Houman as Medical Director - PR Web - August 11th, 2022
- Lanta Flat Belly Shake Reviews - Really Effective for Weight Loss? Urgent Customer WARNING - Outlook India - August 11th, 2022
- Some Women Turn to Self-Managed Abortion as Access Recedes - The New York Times - August 11th, 2022
- Can I Still Get the Abortion Pill? Everything to Know - CNET - August 11th, 2022
- Why You Need To Stop Using Your Android Phone Before Going To Sleep - SlashGear - August 11th, 2022
- What the Tavistock clinics closure means for the trans debate - The Week UK - August 3rd, 2022
- India's First Trans Trainee Pilot Adam Harry's Case That Led DGCA To Work On Policy For Trans Pilots - Outlook India - August 3rd, 2022
- 6 Medical Conditions That Can Cause You to Gain Weight - SciTechDaily - August 3rd, 2022
- Guideline change removes 'demeaning' barrier to hormone therapy - Stuff - August 3rd, 2022
- Injectable HIV Prevention Better Than Pills in Two Trials - Medscape - August 3rd, 2022
- I Tested My Stress and It Was Through the RoofHeres the Expert-Backed Plan Thats Getting Me Through It - Well+Good - August 3rd, 2022
- 7 home remedies for crows feet to keep wrinkles and fine lines at bay - Health shots - August 3rd, 2022
- The Real Effects Owning A Pet Has On Your Body - Health Digest - August 3rd, 2022
- Lets Talk About Misoprostolthe Original Abortion Pill - Ms. Magazine - August 3rd, 2022
- This Period-Tracking Method Will Protect Your Privacy Better Than an App - CNET - August 3rd, 2022
- The circulating 70 kDa heat shock protein (HSPA1A) level is a potential biomarker for breast carcinoma and its progression | Scientific Reports -... - August 3rd, 2022
- Hormone Therapy for Menopause Symptoms - Cleveland Clinic - June 28th, 2022
- Hormone therapy for breast cancer - Mayo Clinic - June 28th, 2022
- Gonadotropin-Releasing Hormone (GnRH): Purpose & Testing - June 28th, 2022
- Family Tree Clinic has broadened its scope of services and its regional impact by helping transgender people get the hormone care they need - Sahan... - June 28th, 2022
- Hot Flashes From Hormone Therapy, Poorer Outcomes in Breast Cancer - Medscape - June 28th, 2022
- Smartphone use increases urination at night: nutritionist - - June 28th, 2022
- How To Track Your Ovulation Most Accurately, According To Ob-Gyns - Women's Health - June 28th, 2022
- Anti-Abortion Centers Find Pregnant Teens Online, Then Save Their Data - Bloomberg - June 28th, 2022
- The most common birth control methods and how effective they are at preventing pregnancy - Yahoo Life - June 28th, 2022
- The Journey To Be Me: The heartbreak, hope and courage of a Maine transgender child - Maine Public - June 18th, 2022
- How To Reintroduce Lactation After Stopping Breastfeeding - Health Essentials from Cleveland Clinic - June 18th, 2022
- Medication abortions are easy to access in Oregon, but how do they work? - Oregon Public Broadcasting - June 18th, 2022
- How does an IUD work and how long does it last? - Reviewed - June 18th, 2022
- Men's Wellness: Being proactive, annual care key to maintaining health - LimaOhio.com - June 18th, 2022
- Hormone-Replacement Therapy Is Life-Changing: What to Consider Before Getting Started - POPSUGAR - June 9th, 2022
- Do You Need Hormone Testing? - Health Essentials from Cleveland Clinic - June 9th, 2022